What do TCR² Therapeutics and Adaptimmune have in common? They’re both T-cell-focused drug developers that have been shedding staff in recent weeks to stay afloat. Now, they’re combining into one company in the latest example of a growing trend for biotech-on-biotech mergers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,